EHA 2023 | The clinical meaning of MRD below the threshold of mCR in AML
Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, explains the clinical meaning of measurable residual disease (MRD) below the threshold of molecular complete remission (mCR) in acute myeloid leukemia (AML). Dr Perl describes different quantitative methods which can be used to determine MRD as the incidence of leukemia-associated mutations in a patient relative to a reference gene. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie, Astellas, BerGenBio, Daiichi Sankyo, Genentech, Immunogen–advisory board
Abbvie, Astellas, Daiichi Sankyo, Foghorn–consulting
Abbvie, Astellas, Daiichi Sankyo, FujiFilm, Syndax–research funding (to institution)
